Literature DB >> 2411858

Altered axonal transport of cytoskeletal proteins in the mutant diabetic mouse.

M Vitadello, G Filliatreau, J L Dupont, R Hassig, A Gorio, L Di Giamberardino.   

Abstract

Polypeptides in the motor axons of the sciatic nerve in 120-day-old normal and diabetic mice C57BL/Ks (db/db) were labeled by injection of [35S]methionine into the ventral horn of the spinal cord. At 8, 15, and 25 days after the injection, the distribution of radiolabeled polypeptides along the sciatic nerve was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Four major radiolabeled polypeptides, tentatively identified as actin, tubulin, and the two lightest subunits of the neurofilament triplet, were studied in both diabetic and control mice. In the diabetic animals, the two polypeptides identified as actin and tubulin showed a reduction of average velocity of migration along the sciatic nerve, resulting in a higher fraction of radioactivity in the proximal part of the sciatic nerve, whereas the front of radioactivity (advancing at maximal velocity) moved at a normal rate. In contrast, both the average and maximal velocities of the two neurofilament subunits were slower in the diabetic mice than in the control mice. These results indicate that the axonal transport of the cytoskeletal proteins is differentially affected in the course of diabetic neuropathy, and may suggest that the impairment concerns mainly the proteins carried by the slowest component of axonal transport.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411858     DOI: 10.1111/j.1471-4159.1985.tb04073.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  A proposal for a classification of neuropathies according to their axonal transport abnormalities.

Authors:  J Jakobsen; P Sidenius; H Braendgaard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

2.  Impaired axonal transport of acetylcholinesterase in the sciatic nerve of alloxan-diabetic rats: effect of ganglioside treatment.

Authors:  P Marini; M Vitadello; R Bianchi; C Triban; A Gorio
Journal:  Diabetologia       Date:  1986-04       Impact factor: 10.122

3.  Diabetic neuropathy in db/db mice develops independently of changes in ATPase and aldose reductase. A biochemical and immunohistochemical study.

Authors:  R Bianchi; C Marelli; P Marini; M Fabris; C Triban; M G Fiori
Journal:  Diabetologia       Date:  1990-03       Impact factor: 10.122

4.  Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes.

Authors:  J G Llewelyn; P K Thomas; S G Gilbey; P J Watkins; J R Muddle
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

5.  Posttranslational modifications of nerve cytoskeletal proteins in experimental diabetes.

Authors:  W G McLean; C Pekiner; N A Cullum; I F Casson
Journal:  Mol Neurobiol       Date:  1992 Summer-Fall       Impact factor: 5.590

6.  Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes.

Authors:  Hsinlin T Cheng; Jacqueline R Dauch; John M Hayes; Yu Hong; Eva L Feldman
Journal:  J Neuropathol Exp Neurol       Date:  2009-11       Impact factor: 3.685

7.  The role of the p75 neurotrophin receptor in the morphology of dorsal root ganglion cells in streptozotocin diabetic mice: effects of sciatic nerve crush.

Authors:  Y Jiang; J Jakobsen
Journal:  Diabetologia       Date:  2004-09-09       Impact factor: 10.122

Review 8.  Criteria for creating and assessing mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; Stephen I Lentz; John L Roberts; Eva L Feldman
Journal:  Curr Drug Targets       Date:  2008-01       Impact factor: 3.465

9.  Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes.

Authors:  Lucy M Hinder; Anuradha Vivekanandan-Giri; Lisa L McLean; Subramaniam Pennathur; Eva L Feldman
Journal:  J Endocrinol       Date:  2013-01-02       Impact factor: 4.286

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.